Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...
February 20, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Gilead (GILD) Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...
Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – – First and Only Treatment That Achieved Statistically ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in ...
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, today announced it has been named to G2's 2025 Best ...